Navigation Links
Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use

Nearly 150,000 PCIs Were Performed on AMI Patients in 2008, According to Millennium Research Group

WALTHAM, Mass., Feb. 18 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will continue to climb steadily through 2013, driven in large part by the adoption of primary percutaneous coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, who accounted for nearly 150,000 PCIs in the US in 2008.

In the past, primary PCI--defined as a PCI performed within 24 hours of the onset of symptoms--was mostly limited to facilities that had surgical back-up present. Studies have shown, however, that AMI patients who undergo primary PCI have improved outcomes over thrombolytics, even without surgical back-up. Experts are now trying to reduce the time it takes to get patients to a cath lab -- in some cases bypassing the emergency room -- which will drive primary PCI adoption and support DES use in AMI patients.

Furthermore, a number of clinical trials in 2007 and 2008 released positive clinical data, which showed that ST-elevation myocardial infarction (STEMI) patients who receive aspiration with stenting have better blood flow, enhanced myocardial function, and lower mortality rates than patients who received angioplasty with stenting or direct stenting.

"The TAPAS trial indicated that STEMI patients treated with aspiration prior to stenting had over 30% lower mortality in the following year compared to those who had angioplasty-with-stent procedures," says Stephanie LaBelle, Senior Analyst at MRG. "As a result, the portion of primary PCIs using aspiration rather than predilation prior to stenting will grow in AMI patients through 2013."

MRG's US Markets for Interventional Cardiology Devices 2009 report provides coverage of key industry trends, including new segments on the treatment of AMI patients and bifurcated lesions, as well as the launch of new devices from Abbott Vascular, Boston Scientific, and Medtronic. Additional leading competitors covered include AngioScore, Cordis, C.R. Bard, Cook Medical, ev3, St. Jude Medical, Terumo Medical, and many more.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101

    Elizabeth Marshall
    Decision Resources Inc.

SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
4. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
5. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
8. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
9. First U.S. Patients Enrolled in the REALISM Continued Access Study
10. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
11. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):